Catarina Horro Pita (Presenter)
LGC - Drug Development Services
Bio: Dr Catarina Horro Pita possesses a BSc in Chemistry and Environmental Chemistry and a PhD in Synthetic Organic Chemistry. After concluding her PhD, she initiated her professional career as a Synthetic Chemist, prior to moving into Analytical Chemistry and Bioanalysis. She currently holds a position as a Principal Scientist in Drug Development Services at LGC, where she has been working for the past ten years. During her time at LGC, she has worked both as a Study Director, which has given her extensive experience in managing GLP and GCP studies, and as a Technical Specialist, leading LC-MS/MS method development projects for the analysis of both xenobiotic compounds and small molecule biomarkers.
Authorship: Catarina Horro Pita
LGC Fordham, UK
| Short Abstract Solubility issues and non-specific binding can be insidious and often overlooked problems in method development and can subsequently cause failures during validation. Both the solubility and binding of an analyte will be affected by the pH and composition of the solution whereas non-specific binding also needs to take into account the nature of the container. These presentations will cover how to assess and differentiate between these phenomena at an early stage in development and discuss common solutions to these issues. |
Long Abstract
Solubility issues and non-specific binding can be insidious and often overlooked problems in method development and can subsequently cause failures during validation. Both the solubility and binding of an analyte will be affected by the pH and composition of the solution whereas non-specific binding also needs to take into account the nature of the container. A common example being an analyte that worked well as a plasma assay but exhibits binding to the same plastic container when in urine. In addition to those observed at the pre-analytical stage, solubility and binding effects can be affected by sample extraction technique and storage time. Part 1 will cover how to assess and differentiate between these phenomena at an early stage in development and discuss common solutions to these issues. Part 2 will present real world case studies illustrating issues with solubility or non-specific binding and how these were overcome. Part 3 is a workshop where the audience will be broken up into teams with a set of “troublesome” method developments. Using the techniques discussed in the first 2 presentations the task will be for the groups to determine what the issue is and suggest possible solutions.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | yes | LGC |
| Board Member | no | |
| Stock | no | |
| Expenses | yes | MSACL |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |